Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.

O'Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X, Liu Y, Bartlett CH, Koehler M, Cristofanilli M, Garcia-Murillas I, Bliss JM, Turner NC. · 2018

Read Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. by O'Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X, Liu Y, Bartlett CH, Koehler M, Cristofanilli M, Garcia-Murillas I, Bliss JM, Turner NC. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5832789.txt.

Description

O'Leary and co-authors test whether early shifts in blood-borne tumor DNA predict benefit from a breast cancer drug pair. Their study appeared in Nature Communications. It draws on the PALOMA-3 trial of palbociclib plus fulvestrant. No marker yet tells who will gain from CDK4/6 blockers.

The team tracked PIK3CA mutations in circulating tumor DNA. Their level after 15 days of treatment strongly foretold progression-free survival. ESR1 mutations, picked up after hormone therapy, were often minor subclones. Their early shifts predicted outcome far more weakly. Subclones thus answered the same drugs in divergent ways.

Catalog record

CREATORO'Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X, Liu Y, Bartlett CH, Koehler M, Cristofanilli M, Garcia-Murillas I, Bliss JM, Turner NC.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE49 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5832789

Browse the full library · About the Tower of Babel